This product consists of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line, in which the AMOT gene has been disrupted to establish a loss-of-function model. The polyclonal nature of the population reflects a heterogeneous mix of edited cells, making it suitable for ensemble studies where the average effect of gene disruption is assessed. As a polyclonal knockout, the product avoids clonal selection artifacts and provides a robust system for investigating AMOT-dependent phenotypes in a lung adenocarcinoma context.
The A-549 host cell line was originally established from the lung adenocarcinoma tissue of a 58-year-old Caucasian male and is widely used as a model for alveolar type II-like epithelial cells. These cells exhibit characteristics of transformed alveolar epithelium and are commonly employed in cancer biology and drug discovery research. Their epithelial origin and tumorigenic properties make them particularly relevant for studying signaling pathways that govern cell proliferation, migration, and polarity, as well as for evaluating therapeutic interventions targeting lung adenocarcinoma.
AMOT (Angiomotin) is a scaffold protein that bridges cell polarity and Hippo signaling. It directly binds LATS1/2 kinases, NF2/Merlin, ZO-1/TJP1, and PATJ, sequestering YAP and TAZ at cell junctions and the actin cytoskeleton. Active Hippo signaling promotes LATS1/2-mediated phosphorylation of AMOT, enhancing its interaction with YAP/TAZ and preventing their nuclear translocation. Additionally, AMOT functions as an angiostatin receptor; angiostatin binding further retains YAP/TAZ in the cytoplasm. Consequently, AMOT suppresses YAP/TAZ-dependent transcriptional programs that drive cell proliferation and migration.
In A-549 cells, AMOT disruption lifts the cytoplasmic sequestration of YAP/TAZ, leading to their nuclear accumulation and transcriptional activation of pro-proliferative and pro-migratory target genes. This phenotype recapitulates oncogenic YAP/TAZ activation frequently observed in non-small cell lung carcinomas and provides a model to dissect Hippo?CWnt crosstalk in tumorigenesis. Knockout cells also exhibit diminished angiostatin sensitivity, enabling studies of AMOT-dependent angiostatin signaling independently of other receptors. Thus, the model captures key aspects of advanced lung adenocarcinoma, including unchecked growth, enhanced invasiveness, and altered anti-angiogenic responses.
This polyclonal knockout population is suitable for diverse assays: Western blotting and RT-qPCR for disruption confirmation; immunofluorescence for YAP/TAZ localization; functional assays such as migration, invasion, and proliferation; co-immunoprecipitation for protein complexes; and phospho-YAP analysis. Applications include Hippo pathway dissection, drug target validation, angiogenesis research, and lung cancer biology. For additional technical information or to discuss custom applications, please contact Ascent Research.
